This antibody is specific to a cell surface glycoprotein of 80‐95 kDa, known as CD44. CD44 is expressed on the surface of lymphocytes, monocytes and granulocytes. CD44 immunostaining is commonly used for the discrimination of urothelial transitional cell carcinoma in-situ from non-neoplastic changes in the urothelium.
